Phio Pharmaceuticals
PHIO
10 hedge funds and large institutions have $127K invested in Phio Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
1.49% less ownership
Funds ownership: 2.31% → 0.82% (-1.5%)
23% less funds holding
Funds holding: 13 → 10 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
67% less capital invested
Capital invested by funds: $389K → $127K (-$262K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Cetera Advisors
Denver,
Colorado
|
+$23.3K |
| 2 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$10.3K |
| 3 |
VF
Virtu Financial
New York
|
+$9.09K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.04K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$131K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$120K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$24.2K |
| 4 |
Renaissance Technologies
New York
|
-$16K |
| 5 |
Morgan Stanley
New York
|
-$190 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $21K | +$9.09K | +1,319 | +62% |
|
|
2
Cetera Investment Advisers
Schaumburg,
Illinois
| $20.7K | +$10.3K | +1,500 | +80% |
|
|
CA
3
Cetera Advisors
Denver,
Colorado
| $20.7K | +$23.3K | +3,380 | New |
|
4
Bank of Montreal
Toronto,
Ontario, Canada
| $17.1K | – | – | – |
|
5
Vanguard Group
Malvern,
Pennsylvania
| $16.6K | – | – | – |
|
|
BCM
6
Bridgeway Capital Management
Houston,
Texas
| $16K | – | – | – |
|
7
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $10K | – | – | – |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $3.87K | -$14 | -2 | -0.3% |
|
|
9
UBS Group
Zurich,
Switzerland
| $923 | +$1.04K | +151 | New |
|
10
Wells Fargo
San Francisco,
California
| $13 | – | – | – |
|
11
BlackRock
New York
| $1 | – | – | – |
|
|
SM
12
Sabby Management
Miami Beach,
Florida
| – | -$131K | -19,188 | Closed |
|
|
AFM
13
Anson Funds Management
Dallas,
Texas
| – | -$120K | -17,492 | Closed |
|
|
14
Citadel Advisors
Miami,
Florida
| – | -$24.2K | -3,538 | Closed |
|
|
15
Renaissance Technologies
New York
| – | -$16K | -2,340 | Closed |
|
|
16
Morgan Stanley
New York
| – | -$190 | -28 | Closed |
|
PHIO Hedge Fund Activity: Q1 2024 in Review
10 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q1 2024, worth a combined $127K — down 67% from $389K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of PHIO and 2 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Cetera Advisors, opening a new position worth an estimated $23.3K. The largest seller was Sabby Management, exiting entirely with an estimated $131K sold.
- 10 institutional investors held Phio Pharmaceuticals (PHIO) as of Q1 2024, down from 13 in Q4 2023.
- Funds reported $127K of Phio Pharmaceuticals stock for Q1 2024, down 67% quarter-over-quarter.
- 2 funds opened new Phio Pharmaceuticals positions in Q1 2024 and 5 closed out, a net change of -3 holders.
- The largest Phio Pharmaceuticals buyer in Q1 2024 was Cetera Advisors, an estimated $23.3K added.
- The largest Phio Pharmaceuticals seller in Q1 2024 was Sabby Management, an estimated $131K sold.
Based on aggregated 13F filings for Q1 2024.